06 / 29 / 2022
Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer
Annals of Oncology, 2022, June 2906 / 23 / 2022
Ascites is a pathological peritoneal fluid accumulation most frequently associated with ovarian cancer, among few others, thereby creating a quite unique tumor microenvironment in which cancer cells spread.
06 / 16 / 2022
In this collaborative work, researchers from Institut Bergonié, Institut Gustave Roussy, and Explicyte, demonstrated that presence of APAP in plasma from cancer patients before they undergo immunotherapy was independently associated with a worse clinical outcome.
06 / 16 / 2022
Check out - it's our favorite image of the month
Summer beginning, look at a real fireworks 🎆! Human cerebral cortex nerve cells lit up on section!
06 / 02 / 2022
Through this study, authors depicted the association between the enrichment of Tumor Associated Macrophages (TAMs) in the Tumor Micro Environment (TME) of Non-Small Cell Lung Cancer (NSCLC) and the resistance to immunotherapy, regardless of the programmed death ligand 1 status.
05 / 31 / 2022
As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.
Olink®’s Target96 biomarker panels are dedicated to many diseases and/or biological processes. You can directly download them from the form below and do not hesitate to let us know your proteomics projects!05 / 29 / 2022
Annals of Oncology, 2022, May 29
A. Bessede, A. Marabelle, JP. Guégan, FX. Danlos, S. Cousin, F. Peyraud, N. Chaput, M. Spalato, G. Roubaud, M. Cabart, M. Khettab, A. Chaibi, C. Rey, I. Nafia, FX. Mahon, JC. Soria, A. Italiano
05 / 26 / 2022
Nature medicine, 2022, May 26
A. Italiano , A. Bessede, M. Pulido, E. Bompas , S. Piperno-Neumann, C. Chevreau, N. Penel, F. Bertucci, M. Toulmonde, C. Bellera, J. P. Guegan, C. Rey, C. Sautès-Fridman , A. Bougoüin, C. Cantarel, M. Kind, M. Spalato, B. Dadone-Montaudie, F. Le Loarer, J. Y. Blay and W. H. Fridman
05 / 19 / 2022
From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.
05 / 12 / 2022
Development and characterization of a novel anti-PD1 resistant sarcoma mouse model
Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.